vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Satellogic Inc. (SATL). Click either name above to swap in a different company.
Satellogic Inc. is the larger business by last-quarter revenue ($6.2M vs $3.9M, roughly 1.6× Citius Pharmaceuticals, Inc.). Satellogic Inc. runs the higher net margin — 488.0% vs -238.2%, a 726.1% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Satellogic Inc. is an American company specializing in Earth-observation satellites, founded in 2010 by Emiliano Kargieman and Gerardo Richarte.
CTXR vs SATL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $6.2M |
| Net Profit | $-9.4M | $30.5M |
| Gross Margin | 80.0% | — |
| Operating Margin | -228.7% | -114.2% |
| Net Margin | -238.2% | 488.0% |
| Revenue YoY | — | — |
| Net Profit YoY | 8.6% | — |
| EPS (diluted) | $-0.38 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $6.2M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $3.4M | ||
| Q2 24 | — | $3.5M |
| Q4 25 | $-9.4M | $30.5M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $-6.7M | ||
| Q1 25 | — | $-32.6M | ||
| Q2 24 | — | $-18.1M |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | -228.7% | -114.2% | ||
| Q3 25 | — | -222.5% | ||
| Q2 25 | — | -141.6% | ||
| Q1 25 | — | -280.9% | ||
| Q2 24 | — | -419.2% |
| Q4 25 | -238.2% | 488.0% | ||
| Q3 25 | — | 109.2% | ||
| Q2 25 | — | -149.8% | ||
| Q1 25 | — | -961.9% | ||
| Q2 24 | — | -517.0% |
| Q4 25 | $-0.38 | $0.24 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.34 | ||
| Q2 24 | — | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $94.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $60.5M |
| Total Assets | $140.4M | $151.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $94.4M | ||
| Q3 25 | — | $28.3M | ||
| Q2 25 | — | $32.6M | ||
| Q1 25 | — | $17.7M | ||
| Q2 24 | — | $25.6M |
| Q4 25 | $80.0M | $60.5M | ||
| Q3 25 | — | $-56.9M | ||
| Q2 25 | — | $-68.1M | ||
| Q1 25 | — | $-83.1M | ||
| Q2 24 | — | $19.1M |
| Q4 25 | $140.4M | $151.3M | ||
| Q3 25 | — | $70.9M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $61.4M | ||
| Q2 24 | — | $76.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-9.5M |
| Free Cash FlowOCF − Capex | — | $-12.8M |
| FCF MarginFCF / Revenue | — | -204.9% |
| Capex IntensityCapex / Revenue | — | 53.6% |
| Cash ConversionOCF / Net Profit | — | -0.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-34.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-9.5M | ||
| Q3 25 | — | $-8.4M | ||
| Q2 25 | — | $-4.3M | ||
| Q1 25 | — | $-4.7M | ||
| Q2 24 | — | — |
| Q4 25 | — | $-12.8M | ||
| Q3 25 | — | $-9.7M | ||
| Q2 25 | — | $-5.1M | ||
| Q1 25 | — | $-6.6M | ||
| Q2 24 | — | — |
| Q4 25 | — | -204.9% | ||
| Q3 25 | — | -267.2% | ||
| Q2 25 | — | -115.3% | ||
| Q1 25 | — | -195.9% | ||
| Q2 24 | — | — |
| Q4 25 | — | 53.6% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | — | 17.5% | ||
| Q1 25 | — | 56.5% | ||
| Q2 24 | — | — |
| Q4 25 | — | -0.31× | ||
| Q3 25 | — | -2.11× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTXR
Segment breakdown not available.
SATL
| Transferred At Point In Time | $5.7M | 91% |
| Other | $547.0K | 9% |
